Dr. Powell Discusses CPI-613 in Hematologic Malignancies
June 11th 2013
Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.